Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2003European Journal of Heart Failure

Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)

View Full Paper
Ask AI
Bookmark
Share

Authors

Jay N. CohnJay N. CohnHeart Failure & TransplantMarc A. PfefferMarc A. PfefferHeart Failure / CardiomyopathyJean L. RouleauJean L. RouleauHeart Failure & Transplant

Discussion

Loading...

Member takes

Implication

Moxonidine SR increases early mortality in HFrEF; challenges central sympathetic inhibition as therapy and reinforces beta-blockade specificity.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohn et al. (2003) studied this question.

synapsesocial.com/papers/6a7cfad8dd834592f30eb6c6https://doi.org/10.1016/s1388-9842(03)00163-6

Topics

Heart failureHFrEF treatment
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure2002 · 101 citations
  2. 2Relationship between plasma norepinephrine and sympathetic neural activity.1983 · 354 citations
  3. 3Suppressing Sympathetic Activation in Congestive Heart Failure1995 · 73 citations
  4. 4Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).1990 · 1,393 citations
  5. 5Effect of Carvedilol on Survival in Severe Chronic Heart Failure2001 · 3,109 citations